<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285153</url>
  </required_header>
  <id_info>
    <org_study_id>ASA-MORT</org_study_id>
    <secondary_id>2012-002235-29</secondary_id>
    <nct_id>NCT02285153</nct_id>
  </id_info>
  <brief_title>Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit</brief_title>
  <official_title>Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Platelets play a central part not just in homeostasis and thrombosis as the primary effector
      cells, but they are also key cells in the regulation of the immunological response to various
      stressors. After activation, platelets release their granules which store different
      inflammatory mediators that induce coagulation, recruit further platelets, activate
      complement, attract neutrophils and leukocytes and regulate the vascular tone. Platelets
      activated by systemic inflammation and infection, may also contribute to the development of
      multiple organ failure. Thus, inhibition of platelet activation may have beneficial effects
      on critically ill patients.

      the investigators hypothesize that acetylsalicylic acid reduces the mortality of medical
      intensive care unit patients. In a retrospective study acetylsalicylic acid use was
      associated with a substantial reduction in a medical intensive care unit population (Winning
      et al., 2010).

      The investigators will conduct a randomized, double-blind study including 460 patients
      (2x230), who will be randomized to receive 100mg acetylsalicylic acid(daily, intravenous) or
      a placebo (0,9% sodium-choride solution) to assess whether acetylsalicylic acid reduces the
      mortality of medical intensive care unit patients.

      Main outcome criteria will be 28/90day-mortality. Furthermore the investigators will assess
      whether acetylsalicylic acid reduces the risk of suffering thromboembolic complications.

      Post-mortem examinations will be conducted in all patients who die in the course of the
      study.

      Furthermore we will assess bleeding rates, intensive care unit mortality and pharmacokinetic
      and pharmacodynamic properties of acetylsalicylic acid in the intensive care unit population.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment of planned number of Subjects was not feasible.
  </why_stopped>
  <start_date type="Actual">November 15, 2011</start_date>
  <completion_date type="Actual">November 10, 2017</completion_date>
  <primary_completion_date type="Actual">September 5, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>28-day Mortality</measure>
    <time_frame>28-days</time_frame>
    <description>Standard outcome measure of investigational intensive care unit trials.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit Mortality</measure>
    <time_frame>up to 90 days after inclusion</time_frame>
    <description>Mortality of patients during their intensive care unit stay, 90 day mortality, potentially longer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Developed a Thrombotic or Embolic Complications During the Trial</measure>
    <time_frame>average 28 days</time_frame>
    <description>clinically relevant thromboembolic events assessed by standard care, potentially longer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Incidences</measure>
    <time_frame>average 28days</time_frame>
    <description>all bleeding incidence during the intensive care unit stay will be recorded. major bleeding criteria are taken from the Thrombolysis in myocardial infarction study (TIMI-Triton-38), potentially longer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Acetylsalicylic acid lysinate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg Acetylsalicylic Acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% sodium-chloride solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium-chloride solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid lysinate</intervention_name>
    <description>100mg intravenously administered Acetylsalicylic Acid lysinate per day</description>
    <arm_group_label>Acetylsalicylic acid lysinate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium-chloride solution</intervention_name>
    <description>Placebo, intravenously administered, daily</description>
    <arm_group_label>0.9% sodium-chloride solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients admitted to an intensive care unit

          -  &gt;18 years of age

        Exclusion Criteria:

          -  known allergy of intolerance to acetylsalicylic acid

          -  recent surgery or planned surgery

          -  active bleeding

          -  known coagulation disorders

          -  discretion of the physician

          -  terminal illness (anticipated life expectancy &lt;3months; e.g. due to cancer)

          -  platelet count &lt;20 000

          -  recent ulcera

          -  recent gastrointestinal bleeding

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Jilma, Ao. Univ.-Prof. Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Department of Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Winning J, Neumann J, Kohl M, Claus RA, Reinhart K, Bauer M, LÃ¶sche W. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med. 2010 Jan;38(1):32-7. doi: 10.1097/CCM.0b013e3181b4275c.</citation>
    <PMID>19770746</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 24, 2012</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2014</study_first_posted>
  <results_first_submitted>August 18, 2019</results_first_submitted>
  <results_first_submitted_qc>November 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 18, 2019</results_first_posted>
  <last_update_submitted>November 28, 2019</last_update_submitted>
  <last_update_submitted_qc>November 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Bernd Jilma</investigator_full_name>
    <investigator_title>Ao. Univ.-Prof. Dr. Bernd Jilma</investigator_title>
  </responsible_party>
  <keyword>acetylsalicylic acid</keyword>
  <keyword>intensive care unit</keyword>
  <keyword>mortality</keyword>
  <keyword>Post mortem examination</keyword>
  <keyword>bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Acetylsalicylic acid lysinate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 26, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02285153/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acetylsalicylic Acid Lysinate</title>
          <description>100mg Acetylsalicylic Acid
Acetylsalicylic acid lysinate: 100mg intravenously administered Acetylsalicylic Acid lysinate per day</description>
        </group>
        <group group_id="P2">
          <title>0.9% Sodium-chloride Solution</title>
          <description>0.9% sodium-chloride solution
0.9% sodium-chloride solution: Placebo, intravenously administered, daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acetylsalicylic Acid Lysinate</title>
          <description>100mg Acetylsalicylic Acid
Acetylsalicylic acid lysinate: 100mg intravenously administered Acetylsalicylic Acid lysinate per day</description>
        </group>
        <group group_id="B2">
          <title>0.9% Sodium-chloride Solution</title>
          <description>0.9% sodium-chloride solution
0.9% sodium-chloride solution: Placebo, intravenously administered, daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="15"/>
                    <measurement group_id="B2" value="63" spread="10"/>
                    <measurement group_id="B3" value="61" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Simplified Acute Physiology Score III</title>
          <description>The Simplified Acute Physiology Score III is a commonly used disease severity score specifically designed for critically ill patients. It was calculated on the day of admission The score may range from 0 to 217 points. The score includes information on conditions that led to ICU admission, underlying diseases, ventilation, catecholamine use, laboratory data Higher scores predicted mortality, while lower scores were associated with survival.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="19"/>
                    <measurement group_id="B2" value="63" spread="13"/>
                    <measurement group_id="B3" value="64" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>28-day Mortality</title>
        <description>Standard outcome measure of investigational intensive care unit trials.</description>
        <time_frame>28-days</time_frame>
        <population>modified Intention to treat population (all patients who received at least a single dose of acetylsalicylic acid)</population>
        <group_list>
          <group group_id="O1">
            <title>Acetylsalicylic Acid Lysinate</title>
            <description>100mg Acetylsalicylic Acid
Acetylsalicylic acid lysinate: 100mg intravenously administered Acetylsalicylic Acid lysinate per day</description>
          </group>
          <group group_id="O2">
            <title>0.9% Sodium-chloride Solution</title>
            <description>0.9% sodium-chloride solution
0.9% sodium-chloride solution: Placebo, intravenously administered, daily</description>
          </group>
        </group_list>
        <measure>
          <title>28-day Mortality</title>
          <description>Standard outcome measure of investigational intensive care unit trials.</description>
          <population>modified Intention to treat population (all patients who received at least a single dose of acetylsalicylic acid)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.57</p_value>
            <p_value_desc>Due to the low number of participants, the results of the statistical tests must be interpreted with caution!</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.434</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.225</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>4.792</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Care Unit Mortality</title>
        <description>Mortality of patients during their intensive care unit stay, 90 day mortality, potentially longer</description>
        <time_frame>up to 90 days after inclusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylsalicylic Acid Lysinate</title>
            <description>100mg Acetylsalicylic Acid
Acetylsalicylic acid lysinate: 100mg intravenously administered Acetylsalicylic Acid lysinate per day</description>
          </group>
          <group group_id="O2">
            <title>0.9% Sodium-chloride Solution</title>
            <description>0.9% sodium-chloride solution
0.9% sodium-chloride solution: Placebo, intravenously administered, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Intensive Care Unit Mortality</title>
          <description>Mortality of patients during their intensive care unit stay, 90 day mortality, potentially longer</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Developed a Thrombotic or Embolic Complications During the Trial</title>
        <description>clinically relevant thromboembolic events assessed by standard care, potentially longer</description>
        <time_frame>average 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylsalicylic Acid Lysinate</title>
            <description>100mg Acetylsalicylic Acid
Acetylsalicylic acid lysinate: 100mg intravenously administered Acetylsalicylic Acid lysinate per day</description>
          </group>
          <group group_id="O2">
            <title>0.9% Sodium-chloride Solution</title>
            <description>0.9% sodium-chloride solution
0.9% sodium-chloride solution: Placebo, intravenously administered, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Developed a Thrombotic or Embolic Complications During the Trial</title>
          <description>clinically relevant thromboembolic events assessed by standard care, potentially longer</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Incidences</title>
        <description>all bleeding incidence during the intensive care unit stay will be recorded. major bleeding criteria are taken from the Thrombolysis in myocardial infarction study (TIMI-Triton-38), potentially longer</description>
        <time_frame>average 28days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylsalicylic Acid Lysinate</title>
            <description>100mg Acetylsalicylic Acid
Acetylsalicylic acid lysinate: 100mg intravenously administered Acetylsalicylic Acid lysinate per day</description>
          </group>
          <group group_id="O2">
            <title>0.9% Sodium-chloride Solution</title>
            <description>0.9% sodium-chloride solution
0.9% sodium-chloride solution: Placebo, intravenously administered, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Incidences</title>
          <description>all bleeding incidence during the intensive care unit stay will be recorded. major bleeding criteria are taken from the Thrombolysis in myocardial infarction study (TIMI-Triton-38), potentially longer</description>
          <units>counts</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.467</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of the Trial: Inclusion until ICU discharge, up to 365 days</time_frame>
      <desc>mortality was the primary endpoint. Therefore death was treated as an endpoint rather than a serious adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Acetylsalicylic Acid Lysinate</title>
          <description>100mg Acetylsalicylic Acid
Acetylsalicylic acid lysinate: 100mg intravenously administered Acetylsalicylic Acid lysinate per day</description>
        </group>
        <group group_id="E2">
          <title>0.9% Sodium-chloride Solution</title>
          <description>0.9% sodium-chloride solution
0.9% sodium-chloride solution: Placebo, intravenously administered, daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Asystolia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colon Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>hypoxic brain damage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Catheter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Obstipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>catheter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Herpes Virus Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study had to be terminated because of a poor recruitment rate. Thus, all results need to be interpreted with great caution. Patients were critically ill. Hence, the occurrence of adverse events should be interpreted accordingly.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bernd Jilma</name_or_title>
      <organization>Medical University of Vienna</organization>
      <phone>+434040029180</phone>
      <email>bernd.jilma@meduniwien.ac.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

